Actuate Therapeutics, Inc. Common stock (ACTU NASDAQ) stock market data APIs
$6.2452
-0.15(-2.4%)
as of July 8, 2025
Try our APIs with
free plan!
Actuate Therapeutics, Inc. Common stock Financial Data Overview
Price chart is built with
Anychart
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Prev. Close
6.2452
Open
6.0983
High
6.5694
Low
5.6772
52 wk Range
5.5-11.99
Market Cap
118 M
Shares Outstanding
19 620 K
EPS
-0.32
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Actuate Therapeutics, Inc. Common stock data using free add-ons & libraries
Get Actuate Therapeutics, Inc. Common stock Fundamental Data
Actuate Therapeutics, Inc. Common stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -0.3
Get Actuate Therapeutics, Inc. Common stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Actuate Therapeutics, Inc. Common stock News
New
Bios 2024 co-invest buys ACTU stock worth $499,996
On June 27, 2025, Bios 2024 Co-Invest, LP, a director and 10% owner of Actuate Therapeutics , Inc. (NASDAQ:ACTU), purchased 71,428 shares of common stock at $7.0, for a total value of $499,996. The p...
Actuate therapeutics director Kreis buys $499,996 in shares
Director Leslie W. Kreis, along with entities he is affiliated with, reported purchasing 71,428 shares of Actuate Therapeutics , Inc. (NASDAQ:ACTU) common stock at a price of $7.0 per share, for a to...
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elrag...
Actuate Therapeutics identifies biomarkers for pancreatic cancer drug
CHICAGO/FORT WORTH - Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biotech company currently trading at $7.49 per share, has identified seven biomarkers that may help predict which metast...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
